In order better to protect public health and avoid any unnecessary duplication of effort during the examination of application for a marketing authorization for medicinal products, Member States should systematically prepare assessment reports in respect of each medicinal product which is authorized by them, and exchange the reports upon request. Furthermore, a Member State should be able to suspend the examination of an application for authorization to place a medicinal product on the market which is currently under active consideration in another Member State with a view to recognizing the decision reached by the latter Member State.
Recital 15, Directive (EU) 2001/83
Judgment of the Court (Second Chamber) of 23 April 2026. EG Labo Laboratoires Eurogenerics SAS and Theramex France SAS v Agence nationale deDecision
Recitals 2, 3, 9, 10 and 15 of Directive 2001/83 read as follows: The essential aim of any rules governing the production, distribution and use of medicinal products must be to safeguard public health However, this objective must be …
23 Apr 2026 · 62024CJ0118
Opinion of Mr Advocate General Geelhoed delivered on 7 February 2002. Ferring Arzneimittel GmbH v Eurim-Pharm Arzneimittel GmbH.Decision
However, unnecessary duplication during the course of this examination is to be avoided. [See also on this point the fifteenth recital of Directive 2001/83.] Thus Point 8 of the second paragraph of Article 4 of Directive 65/65 establishes …
7 Feb 2002 · 62000CC0172